Pharmacological treatments in critical burn patients with augmented renal clearance

doi:10.3877/cma.j.issn.1673-9450.2023.03.015

Abstract

Abstract:

Augmented renal clearance (ARC) refers to significant enhancement of kidney clearance function, which is more common in critical patients and in critical burn patients, but it is often overlooked. ARC increases the clearance rate of drug, and the target blood concentration cannot be reached at conventional therapeutic doses. ARC occurs mostly at the high metabolic stage in critical burn patients while the decreased plasma concentration of drugs cleared by the kidney will affect the therapeutic effects seriously. The definition, pathogenesis, risk factors of ARC, and the evaluation of the pharmacokinetics and pharmacodynamics of related drugs and the dose adjustment methods after critical burn complicated with ARC are reviewed in this article, to improve the recognition of ARC in critical burns and to provide reference for rational drug use in clinical work.

Key words: Augmented renal clearance, Critical burn, Creatinine clearance, Pharmacokinetics

Xiaobin Liu, Feng Zhu. Pharmacological treatments in critical burn patients with augmented renal clearance[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(03): 260-264.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhssyxfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1673-9450.2023.03.015

https://zhssyxfzz.cma-cmc.com.cn/EN/Y2023/V18/I03/260

References 48

[1]	Cook AM, Hatton-Kolpek J. Augmented Renal Clearance[J]. Pharmacotherapy，2019，39(3)：346-354.
[2]	Loirat P, Rohan J, Baillet A，et al. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin[J]．The New England Journal of Medicine, 1978，299(17)：915-919.
[3]	Carlier M, De Waele JJ. Identifying patients at risk for augmented renal clearance in the ICU - limitations and challenges[J]. Crit Care，2013，17(2)：130.
[4]	De Waele JJ, Dumoulin A, Janssen A，et al. Epidemiology of augmented renal clearance in mixed ICU patients[J]. Minerva Anestesiol，2015，81(10)：1079-1085.
[5]	Garrelts JC, Peterie JD. Altered vancomycin dose vs. serum concentration relationship in burn patients[J]. Clinical Pharmacology and Therapeutics, 1988，44(1)：9-13.
[6]	Morbitzer KA, Jordan JD, Rhoney DH. Vancomycin pharmacokinetic parameters in patients with acute brain injury undergoing controlled normothermia, therapeutic hypothermia, or pentobarbital infusion[J]. Neurocrit Care, 2015，22(2)：258-264.
[7]	Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, et al. Augmented renal clearance in critically ill patients: a systematic review[J]. Clin Pharmacokinet，2018，57(9)：1107-1121.
[8]	Udy AA, Roberts JA, Shorr AF，et al. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: Identifying at-risk patients[J]. Crit Care，2013，17：R35.
[9]	Barletta JF, Mangram AJ, Byrne M，et al. Identifying augmented renal clearance in trauma patients: validation of the augmented renal clearance in trauma intensive care (arctic) scoring system[J]. J Trauma Acute Care Surg, 2017，82(4)：665-671.
[10]	Udy AA, Baptista JP, Lim NL, et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations[J]. Crit Care Med, 2014, 42(3): 520-527.
[11]	杨柳，角述兰，思永玉，等．不同烧伤程度患者靶控输注丙泊酚的药代动力学[J]．临床麻醉学杂志，2018，34(8)：777-781.
[12]	Huttner A, Von Dach E, Renzoni A, et al. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study[J]. International Journal of Antimicrobial Agents, 2015，45(4)：385-392.
[13]	Udy AA, Lipman J, Jarrett P, et al. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance？[J]. Crit Care，2015，19(1)：28.
[14]	Selig DJ, Akers KS, Chung KK, et al. Comparison of piperacillin and tazobactam pharmacokinetics in critically ill patients with trauma or with burn[J]. Antibiotics (Basel), 2022，11(5)：618.
[15]	Torian SC, Wiktor AJ, Roper SE, et al. Burn injury and augmented renal clearance: a case for optimized piperacillin-tazobactam dosing[J]. J Burn Care Res，2023，44(1)：203-206.
[16]	Conil JM, Georges B, Fourcade O, et al. Intermittent administration of ceftazidime to burns patients: influence of glomerular filtration[J]. Int J Clin Pharmacol Ther，2007，45(3)：133-142.
[17]	Boucher BA, Hickerson WL, Kuhl DA, et al. Imipenem pharmacokinetics in patients with burns[J]. Clin Pharmacol Ther，1990，48(2)：130-137.
[18]	Selig DJ, Akers KS, Chung KK, et al. Meropenem pharmacokinetics in critically ill patients with or without burn treated with or without continuous veno-venous haemofiltration[J]. Br J Clin Pharmacol，2022，88(5)：2156-2168.
[19]	Bakke V, Sporsem H, Von der Lippe E, et al. Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study[J]. Acta Anaesthesiol Scand, 2017，61(6)：627-635.
[20]	Conil JM, Favarel H, Laguerre J, et al. Continuous administration of vancomycin in patients with severe burns[J]. Presse Med，1994，23(34)：1554-1558.
[21]	Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper[J]. Intensive Care Med，2020，46(6)：1127-1153.
[22]	Hu S, Wang T, You H, et al. Plasma trough concentration distribution and safety of high-dose teicoplanin for patients with augmented renal clearance[J]. J Clin Pharm Ther，2022，47(10)：1548-1555.
[23]	Steer JA, Papini RP, Wilson AP, et al. Pharmacokinetics of a single dose of teicoplanin in burn patients[J]. J Antimicrob Chemother，1996，37(3)：545-553.
[24]	Carrié C, Delzor F, Roure S, et al. Population pharmacokinetic study of the suitability of standard dosing regimens of amikacin in critically ill patients with open-abdomen and negative-pressure wound therapy[J]. Antimicrob Agents Chemother，2020，64(4)：e02098-02119.
[25]	Zaske DE, Sawchuk RJ, Gerding DN, et al. Increased dosage requirements of gentamicin in burn patients[J]. The Journal of Trauma, 1976，16(10)：824-828.
[26]	Borra LC, Bosch TM, van Baar ME, et al. Adequacy of a hospital-wide standard dose of 7mg/kg bodyweight gentamicin sufficient to achieve an adequate prophylactic maximum serum concentration (cmax) in burn patients undergoing surgical burn wound treatment[J]. Burns, 2016，42(8)：1819-1824.
[27]	Bracco D, Landry C, Dubois MJ, et al. Pharmacokinetic variability of extended interval tobramycin in burn patients[J]. Burns，2008，34(6)：791-796.
[28]	Hoey LL, Tschida SJ, Rotschafer JC, et al. Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries[J]. J Burn Care Rehabil. 1997，18(2)：116-124.
[29]	Roberts JA, Cotta MO, Cojutti P, et al. Does critical illness change levofloxacin pharmacokinetics？[J]. Antimicrob Agents Chemother，2015，60(3)：1459-1463.
[30]	Kiser TH, Hoody DW, Obritsch MD, et al. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury[J]. Antimicrob Agents Chemother，2006，50(6)：1937-1945.
[31]	Lesne-Hulin A, Bourget P, Ravat F, et al. Clinical pharmacokinetics of ciprofloxacin in patients with major burns[J]. Eur J Clin Pharmacol，1999，55(7)：515-519.
[32]	Van Daele R, Wauters J, Lagrou K, et al. Pharmacokinetic variability and target attainment of fluconazole in critically ill patients[J]. Microorganisms，2021，9(10)：2068.
[33]	Han S, Kim J, Yim H, et al. Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with candida infection[J]. Antimicrob Agents Chemother, 2013，57(2)：1006-1011.
[34]	Akers KS, Rowan MP, Niece KL, et al. Antifungal wound penetration of amphotericin and voriconazole in combat-related injuries: case report[J]. BMC Infect Dis，2015，15：184.
[35]	Asensio MJ, Sánchez M, Galván B, et al. Micafungin at a standard dosage of 100 mg/day achieves adequate plasma exposure in critically ill patients with severe burn injuries[J]. Intensive Care Med，2015，41(2)：371-372.
[36]	Trupkovic T, Kinn M, Kleinschmidt S. Analgesia and sedation in the intensive care of burn patients: results of a European survey[J]. Journal of Intensive Care Medicine, 2011，26(6)：397-407.
[37]	Bae JY, Choi DY, Woo CH, et al. The BIS and hemodynamic changes in major burn patients according to a slow infusion of propofol for induction[J]. Korean Journal of Anesthesiology, 2011，60(3)：161-166.
[38]	Martyn J, Greenblatt DJ. Lorazepam conjugation is unimpaired in burn trauma[J]. Clin Pharmacol Ther，1988，43(3)：250-255.
[39]	Perreault S, Choinière M, du Souich PB, et al. Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries[J]. The Annals of Pharmacotherapy, 2001，35(12)：1588-1592.
[40]	Herman RA, Veng-Pedersen P, Miotto J, et al. Pharmacokinetics of morphine sulfate in patients with burns[J]. The Journal of Burn Care & Rehabilitation，1994，15(2)：95-103.
[41]	Dwersteg JF, Pavlin EG, Heimbach DM. Patients with burns are resistant to atracurium[J]. Anesthesiology, 1986，65(5)：517-520.
[42]	Han TH, Martyn JA. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus[J]. British Journal of Anaesthesia, 2009，102(1)：55-60.
[43]	Martyn JA, Chang Y, Goudsouzian NG, et al. Pharmacodynamics of mivacurium chloride in 13- to 18-yr-old adolescents with thermal injury[J]．British Journal of Anaesthesia, 2002，89(4)：580-585.
[44]	Cato LD, Bailiff B, Price J, et al. Heparin resistance in severe thermal injury: a prospective cohort study[J]. Burns Trauma. 2021，9：tkab032.
[45]	Lu P, Harms KA, Paul E, et al. Venous thromboembolism in burns patients: are we underestimating the risk and underdosing our prophylaxis？[J]. J Plast Reconstr Aesthet Surg, 2021，74(8)：1814-1823.
[46]	Lin H, Faraklas I, Saffle J, et al. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients[J]. J Trauma, 2011，71(6)：1557-1561.
[47]	Bilbao-Meseguer I, Barrasa H, Asín-Prieto E, et al. Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function[J]. Pharmaceutics, 2021，13(10)：1690.
[48]	Sime FB, Roberts JA, Jeffree RL, et al. Population pharmacokinetics of levetiracetam in patients with traumatic brain injury and subarachnoid hemorrhage exhibiting augmented renal clearance[J]. Clin Pharmacokinet，2021，60(5)：655-664.

Please choose a citation manager

Content to export